Livalo: Phase IV data

The double-blind, U.S. Phase IV PREVAIL trial in 328 patients with primary hyperlipidemia or mixed dyslipidemia showed that once-daily 4 mg Livalo led to a median percent reduction in LDL-C, the primary endpoint, of 38.1% from baseline to week 12 vs. 26.4% for once-daily 40 mg pravastatin. Livalo also reduced total cholesterol by 25.8% and APOB by 26.9% vs. 18.3% and 17.7%, respectively, for pravastatin. Additionally, Livalo significantly reduced LDL-P concentration by 517 nmol/L vs. 396 nmol/L for pravastatin (p<0.001). Furthermore, Livalo led to a significant mean percent increase in HDL-P concentration of 9.6% vs. 7% for pravastatin (p=0.045). Data were presented at the National Lipid Association meeting in Scottsdale. ...